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 The spectrum of liver disease ranges from non-
alcoholic fatty liver disease (NAFLD) and progresses
to chronic liver disease (CLD) and subsequently
liver cirrhosis (LC).
 Liver disease is a risk factor for surgical
complications and a relative contraindication to
bariatric surgery.
 This study evaluates early outcomes after bariatric
surgery in patients with CLD and LC.
 Patients with CLD and LC undergoing bariatric
surgery have an increased rate of in-house mortality
as well as length of hospital stay compared to
patients without liver disease. However, these rates
may not be clinically significant.
 Bariatric surgery can be safely performed in
appropriately selected patients with CLD and LC
following preoperative optimization.
 139,952 patients were analyzed (RYGB 36.6%,
female 78.6%, age 44.7±12 years).
 CLD was listed in 17,423 (12.4%) patients, including
818 (0.6%) with LC.
 Non-alcoholic fatty liver disease was the most
common cause of CLD.
 Patients with LC were more likely to be older, male,
and have diabetes mellitus and hyperlipidemia.
37.7% of LC and 42.1% of non-cirrhotic CLD patients
underwent RYGB.
 Transfusion, length of stay, and total charges were
higher in the LC group.
 In-hospital mortality was higher in CLD (0.1%) and
LC (<0.3%).
 In MVA, LC was an independent predictor of LHS
(Odds Ratio (OR): 1.82, 95% CI: 1.25-2.67) but non-
cirrhotic CLD was not a predictor of LHS.
 Subgroup MVA in CLD showed RYGB was
independently associated with LHS (OR: 1.85, 95%
CI: 1.53-2.25).
 Minambres, et al. Outcomes of Bariatric Surgery in
Patients with Cirrhosis. Obesity Surgery, col 29.2.
February 2019.
 Marengo, et al. Progression and Natural History of
Nonalcoholic Fatty Liver Disease in Adults. Clinics in Liver
Disease, vol. 20.2. May 2016
 This is a retrospective analysis of the 2012–2016
Healthcare Cost and Utilization Project-National
Inpatient Sample.
 Adult patients with obesity undergoing
laparoscopic sleeve gastrectomy (SG) or Roux-en-Y
gastric bypass (RYGB) were studied.
 CLD and LC were identified along with patient
comorbidities.
 Outcomes were Long Hospital Stay (LHS) defined as
≥5 days, blood product transfusion, total hospital
charges, and in-hospital mortality.




SD: Standard Deviation; CLD: Chronic Liver Disease; USD: United States Dollar; 
IQR: Interquartile Range
* P value < 0.05 in comparison to patients without chronic liver disease 
P value < 0.05 in comparison to patients with non-cirrhotic CLD
† Number of observation ≤10 has not disclosed based on Healthcare Cost 
and Utilization Project agreement









Age, year, mean ± SD 44.6±12 45.1±11.8 53.3±9.7*
Male Gender, n (%) 25,756 (21%) 3890 (23.4%) 239 (29.2%)*
Co-morbidities, n (%)
Diabetes Mellitus 33,997 (35.1%) 5919 (45.5%)* 522 (70.4%)*
Hypertension 55,591 (45.4%) 6745 (40.6%)* 195 (23.8%)*
Hyperlipidemia 42,338 (34.6%) 7237 (43.6%)* 350 (42.8%)*
Chronic pulmonary disease 23,031 (18.8%) 3497 (21.1%) 184 (22.5%)
Obstructive Sleep Apnea 50,446 (41.2%) 8394 (50.6) * 445 (54.4%) *
Congestive Heart Failure 1529 (1.8%) 214 (1.9%) 21 (3.6%) *









Roux-en-Y Gastric Bypass 43,914 (35.8%) 6991 (42.1%)* 308 (37.7%)
In-hospital Outcomes
Blood Product Transfusion 1081 (0.9%) 158 (1%) 28 (3.4%)*
Length of Stay ≥5 days 2619 (2.1%) 403 (2.4%) 37 (4.5%)*
Total Charges, USD, median (IQR) 41,360 (28,270) 42,600 (29,900) 46,640 (32,550)*
Mortality 38 (0.03%) 12 (0.1%)* (<0.3%) †
Comparison of Procedures and Outcomes
Comparison of demographic and comorbidities
